On December 19, 2025, New York Governor Kathy Hochul vetoed the New York Health Information Privacy Act (“NYHIPA”).  While NYHIPA bore similarities to Washington’s My Health My Data Act (“MHMD”) and Nevada’s Health Privacy Law (“SB 370”), it had several provisions that would have raised novel compliance and legal questions.

  • Regulated Entities. NYHIPA’s scope would have applied more broadly than other similar laws, including to entities processing regulated health information of an individual who is physically present in New York during the period the individual is located in the state.  It is not clear how such a provision would have applied where companies do not collect precise geolocation in the regular course or do not link such geolocation data with account-level data.
  • Regulated Health Information. NYHIPA would have governed “regulated health information” (“RHI”), defined as “any information that is reasonably linkable to an individual, or a device, and is collected or processed in connection with the physical or mental health of an individual.”  In comparison, MHMD and SB 370 are focused on personal information linked or reasonably linkable to a consumer and that identifies the consumer’s health status.  Especially since NYHIPA’s definition lacked any examples of RHI, it was unclear whether and how the scope of the definition was intended to differ than other state laws.
  • “Valid Authorization” Requirements. NYHIPA required regulated entities to obtain “valid authorization” prior to processing RHI, unless the processing is “strictly necessary” for one of seven enumerated purposes.  Where required, NYHIPA included a novel standard for valid authorization, including that authorization must be executed “at least twenty-four hours after an individual creates an account or first uses the requested product or service.”
  • Retention Schedule. NYHIPA would have required regulated entities to maintain a publicly available retention schedule and dispose of an individual’s RHI pursuant to such schedule within a reasonable time, and “in no event later than sixty days, after it is no longer necessary to maintain for the permissible purpose or purposes identified.”
  • Exemptions. NYHIPA raised questions about the interplay with federal sectoral privacy laws.  While it included exemptions for protected health information (“PHI”) collected by covered entities or business associates subject to the Health Insurance Portability and Accountability Act, as amended, and its implementing regulations (“HIPAA”), it did not include other standard exemptions.  For example, it lacked exemptions found in MHMD and SB 370 for financial data regulated by the Gramm-Leach Bliley Act (“GLBA”) and Fair Credit Reporting Act (“FCRA”), employee data, data used for public health purposes as described in HIPAA (e.g., adverse event reporting), and data that has been de-identified in accordance with HIPAA.
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Libbie Canter Libbie Canter

Libbie Canter represents a wide variety of multinational companies on managing privacy, cyber security, and artificial intelligence risks, including helping clients with their most complex privacy challenges and the development of governance frameworks and processes to comply with U.S. and global privacy laws.

Libbie Canter represents a wide variety of multinational companies on managing privacy, cyber security, and artificial intelligence risks, including helping clients with their most complex privacy challenges and the development of governance frameworks and processes to comply with U.S. and global privacy laws. She routinely supports clients on their efforts to launch new products and services involving emerging technologies, and she has assisted dozens of clients with their efforts to prepare for and comply with federal and state laws, including the California Consumer Privacy Act, the Colorado AI Act, and other state laws. As part of her practice, she also regularly represents clients in strategic transactions involving personal data, cybersecurity, and artificial intelligence risk and represents clients in enforcement and litigation postures.

Libbie represents clients across industries, but she also has deep expertise in advising clients in highly-regulated sectors, including financial services and digital health companies. She counsels these companies — and their technology and advertising partners — on how to address legacy regulatory issues and the cutting edge issues that have emerged with industry innovations and data collaborations.

Chambers USA 2026 ranks Libbie in Band 2 Nationwide for both Privacy & Data Security: Privacy and Privacy & Data Security: Healthcare.Chambers USA notes, Libbie is “incredibly sharp and really thorough. She can do the nitty-gritty, in-the-weeds legal work incredibly well but she also can think of a bigger-picture business context and help to think through practical solutions.”

Photo of Elizabeth Brim Elizabeth Brim

Elizabeth Brim provides strategic advice to clients across the health care, life sciences, digital health, and technology sectors, helping them navigate complex privacy, regulatory, and compliance issues involving health and other personal information.

Elizabeth advises clients on compliance with evolving privacy, data governance…

Elizabeth Brim provides strategic advice to clients across the health care, life sciences, digital health, and technology sectors, helping them navigate complex privacy, regulatory, and compliance issues involving health and other personal information.

Elizabeth advises clients on compliance with evolving privacy, data governance, and regulatory frameworks governing the collection, use, disclosure, and protection of health, genetic, consumer health, and other sensitive data. Her work includes counseling on HIPAA, state privacy laws, information blocking requirements, TEFCA, and other federal and state laws affecting health information, digital health technologies, and privacy compliance more broadly.

Elizabeth’s experience spans a broad range of privacy, data governance, cybersecurity, and regulatory issues arising in connection with innovative products and services, artificial intelligence and other emerging technologies, clinical trials and research initiatives, strategic transactions, and commercial arrangements. She regularly advises clients on complex issues involving data governance, privacy compliance, and the protection and exchange of health and other sensitive information.

Elizabeth also advises clients on related health care regulatory and compliance matters, including fraud and abuse, corporate practice of medicine, and other requirements affecting innovative care delivery models.

Elizabeth maintains an active pro bono practice, which includes assisting nonprofit entities with data privacy compliance and vendor contracting.

Elizabeth is an author of the American Health Law Association treatise, Pricing, Market Access, and Reimbursement Principles: Drugs, Biologicals and Medical Devices and the U.S. chapter of the Global Legal Insights treatise, Pricing & Reimbursement Laws and Regulations.

Photo of Ariel Dukes Ariel Dukes

Ariel Dukes is an associate in the firm’s Washington, DC office and a member of the Data Privacy and Cybersecurity Practice Group.

Ariel counsels clients on data privacy, cybersecurity, and artificial intelligence. Her practice includes partnering with clients on compliance with comprehensive privacy…

Ariel Dukes is an associate in the firm’s Washington, DC office and a member of the Data Privacy and Cybersecurity Practice Group.

Ariel counsels clients on data privacy, cybersecurity, and artificial intelligence. Her practice includes partnering with clients on compliance with comprehensive privacy laws, FTC and consumer protection laws and guidance, and laws governing the handling of health-related data. Additionally, Ariel routinely counsels clients on drafting and negotiating privacy terms with vendors and third parties, developing privacy notices and consent forms, and responding to regulatory inquiries regarding privacy and cybersecurity topics. Ariel also advises clients on trends in artificial intelligence regulations and helps design governance programs for the development and deployment of artificial intelligence technologies across a number of industries.

Photo of Kyle Falkner Kyle Falkner

Kyle Falkner is an associate in the firm’s Washington, DC office. He is a member of the Data Privacy and Cybersecurity Practice Group and the Health Care Practice Group.

Kyle advises clients on a wide range of data privacy, technology, and health care…

Kyle Falkner is an associate in the firm’s Washington, DC office. He is a member of the Data Privacy and Cybersecurity Practice Group and the Health Care Practice Group.

Kyle advises clients on a wide range of data privacy, technology, and health care issues. He assists clients in complying with U.S. state and federal privacy laws as well as federal health care laws and regulations.

Kyle also maintains an active pro bono practice focused on supporting international human rights initiatives and assisting small businesses and non-profits with data privacy compliance.